#151472

Anti-EBNA2 [PE2]

Cat. #151472

Anti-EBNA2 [PE2]

Cat. #: 151472

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-5 days

Target: Epstein Barr Virus Encoded Nuclear Antigen 2 (EBNA2)

Class: Monoclonal

Application: IHC ; IF ; IP ; WB ; ChIP-seq

Reactivity: Human ; Virus

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Martin Rowe

Institute: University of Birmingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-EBNA2 [PE2]
  • Clone: PE2
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 52 kDa
  • Reactivity: Human ; Virus
  • Host: Mouse
  • Application: IHC ; IF ; IP ; WB ; ChIP-seq
  • Description: Monoclonal antibody directed at large T antigen of SV40, valuable for investigation into other SV40 tumour antigens and polyomaviruses.
  • Immunogen: Recombinant fusion protein against EBNA2The immunogen was a beta-gal fusion protein from plasmid pKH-2A10 that contains aa 341-480 of B95.8 type EBNA2A (Fig 4 in Young et al 1989)
  • Immunogen uniprot id: P12978
  • Isotype: IgG1 kappa
  • Myeloma used: P3X63Ag8.653
  • Recommended controls: Immunohistochemistry (Acetone fixed): EBV positive Raji cell Line. Western blotting: B95-8 cell

Target Details

  • Target: Epstein Barr Virus Encoded Nuclear Antigen 2 (EBNA2)
  • Molecular weight: 52 kDa
  • Tissue cell line specificity: Immunohistochemistry (Acetone fixed): EBV positive Raji cell Line. Western blotting: B95-8 cell
  • Target background: The Epstein-Barr Virus (EBV), also called Human herpesvirus 4 (HHV-4), is a virus of the herpes family and is one of the most common viruses in humans. EBNA2 is one of the few genes of Epstein-Barr virus which are necessary for immortalization of human primary B lymphocytes. EBV is associated with several B-cell lymphomas and epithelial nasopharyngeal carcinoma. The EBNA2 protein acts as a transcriptional activator of several viral and cellular genes. There are two alternative forms of EBNA2: EBNA2A and EBNA2B. Anti-EBNA2 helped determine the subcellular localisation of the EBNA2 protein to the nuclei of transfected cells. This antibody recognises a shared epitope between the EBNA 2A and 2B proteins. EBNA2 expression in nasopharyngeal carcinoma biopsies was studied more extensively with anti-EBNA2.

Applications

  • Application: IHC ; IF ; IP ; WB ; ChIP-seq

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4° C

References

  • Brocard et al. 2018. Nucleic Acids Res. 46(7):3707-3725. PMID: 29385536.
  • Wille et al. 2017. J Virol. 91(5):. PMID: 28003489.
  • David et al. 2017. Haematologica. :. PMID: 28232371.
  • c-Myc dysregulation is a co-transforming event for nuclear factor-B activated B cells.
  • Restricted TET2 Expression in Germinal Center Type B Cells Promotes Stringent Epstein-Barr Virus Latency.
  • Wille et al. 2016. J Virol. :. PMID: 28003489.
  • Wang et al. 2015. J Virol. :. PMID: 26719268.
  • Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
  • Pujals et al. 2015. Autophagy. :. PMID: 26565591.
  • Constitutive autophagy contributes to resistance to TP53-mediated apoptosis in Epstein-Barr virus-positive latency III B-cell lymphoproliferations.
  • Gibson et al. 2011. Am J Surg Pathol. 35(6):807-15. PMID: 21552113.
  • EBV-positive extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in the posttransplant setting: a distinct type of posttransplant lymphoproliferative disorder?
  • Boshoff et al. 1998. Blood. 91(5):1671-9. PMID: 9473233.
  • Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice.
  • Brink et al. 1997. J Clin Pathol. 50(11):911-8. PMID: 9462239.
  • Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas.
  • Niedobitek et al. 1995. Blood. 86(2):659-65. PMID: 7605996.
  • Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
  • Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.
  • Rowe et al. 1991. J Exp Med. 173(1):147-58. PMID: 1845872.
  • Young et al. 1989. N Engl J Med. 321(16):1080-5. PMID: 2552313.
  • Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.
  • Young et al. 1988. J Gen Virol. 69 ( Pt 5):1051-65. PMID: 2836550.
  • Epstein-Barr virus gene expression in nasopharyngeal carcinoma.